Covalent immobilization of coagulation factor VIII on magnetic nanoparticles for aptamer development
Source abstract
Abstract
Introduction: Magnetic nanoparticles (MNPs) are one of the most useful particulate systems in analytical applications such as specific aptamer selection. Proteins are the most noted targets of aptamer selection. Generally, covalently immobilized protein coated MNPs are more stable structures. Methods: In this study, coagulation factor VIII (FVIII) was immobilized on MNPs. A silica coating provided isocyanate functional groups was considered to interact covalently with reactive groups of the protein, resulting in a stable protein immobilization. The reactions was run in dried toluene. At end, these MNPs were applied for affinity determination of a previously selected FVIII specific aptamers. Results: Immobilization of 1 mg FVIII (~ 3 nmol) on 5 mg particles was achieved with no significant particle aggregation. Using a fluorescence-based method, affinity measurement resulted in a calculated dissociation constant of 120 ± 5.6 nM for the FVIII-specific aptamer to the FVIII-coated MNPs. Conclusion: The final product could be a suitable protein-coated solid support for magnetic-based aptamer selection processes.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Biosensing Techniques and Applications · Protein purification and stability · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
References (59)
Show source-provided references
1. 10.1002/aoc.351810.1002/aoc.3518 ↗
2. 10.1016/j.materresbull.2015.10.00210.1016/j.materresbull.2015.10.002 ↗
3. 10.1016/j.jechem.2016.10.01510.1016/j.jechem.2016.10.015 ↗
4. 10.1007/s10854-017-7286-710.1007/s10854-017-7286-7 ↗
5. 10.1016/j.cej.2012.11.04310.1016/j.cej.2012.11.043 ↗
6. 10.1016/j.msec.2017.03.20810.1016/j.msec.2017.03.208 ↗
7. 10.1016/j.jiec.2013.12.09810.1016/j.jiec.2013.12.098 ↗
8. 10.1016/j.jiec.2014.09.04310.1016/j.jiec.2014.09.043 ↗
9. 10.1016/j.jmmm.2016.03.01410.1016/j.jmmm.2016.03.014 ↗
10. Amiri M · J Mater Sci Mater Electron · 2017 · 1
11. 10.1007/s10876-016-1002-210.1007/s10876-016-1002-2 ↗
12. 10.1016/j.partic.2015.12.00310.1016/j.partic.2015.12.003 ↗
13. 10.1002/anie.20060286610.1002/anie.200602866 ↗
14. 10.1002/jbm.a.3565410.1002/jbm.a.35654 ↗
15. 10.1517/17425247.2014.92450110.1517/17425247.2014.924501 ↗
16. 10.3390/molecules19081146510.3390/molecules190811465 ↗
17. 10.2174/157341371266615121023000210.2174/1573413712666151210230002 ↗
18. 10.1088/1468-6996/16/2/02350110.1088/1468-6996/16/2/023501 ↗
19. 10.1016/j.jconrel.2016.10.02310.1016/j.jconrel.2016.10.023 ↗
20. 10.1016/j.ab.2016.12.00710.1016/j.ab.2016.12.007 ↗
21. 10.1007/s10529-015-1977-z10.1007/s10529-015-1977-z ↗
22. 10.1021/acs.bioconjchem.6b0050410.1021/acs.bioconjchem.6b00504 ↗
23. 10.1002/bit.2319110.1002/bit.23191 ↗
24. 10.1007/s40242-016-6251-y10.1007/s40242-016-6251-y ↗
25. 10.1021/cm071368z10.1021/cm071368z ↗
26. 10.1016/j.jmmm.2009.07.07510.1016/j.jmmm.2009.07.075 ↗
27. 10.1002/smll.20050036010.1002/smll.200500360 ↗
28. 10.1016/j.colsurfa.2004.03.00410.1016/j.colsurfa.2004.03.004 ↗
29. 10.1016/j.cej.2011.10.09710.1016/j.cej.2011.10.097 ↗
30. 10.1039/C0JM02300K10.1039/C0JM02300K ↗
31. 10.1016/j.dyepig.2011.01.01210.1016/j.dyepig.2011.01.012 ↗
32. 10.1021/la903008z10.1021/la903008z ↗
33. 10.1039/C5RA10356H10.1039/C5RA10356H ↗
34. 10.1016/j.materresbull.2014.04.01910.1016/j.materresbull.2014.04.019 ↗
35. Vahidi H · Iran J Pharm Res · 2017 · 16 · 734
36. 10.1039/C6RA16564H10.1039/C6RA16564H ↗
37. 10.1016/j.jssc.2017.06.01310.1016/j.jssc.2017.06.013 ↗
38. 10.1016/j.bej.2015.12.01310.1016/j.bej.2015.12.013 ↗
39. 10.1016/j.apsusc.2015.01.21110.1016/j.apsusc.2015.01.211 ↗
40. 10.1007/s10854-015-3198-610.1007/s10854-015-3198-6 ↗
41. 10.1016/j.microc.2009.10.01110.1016/j.microc.2009.10.011 ↗
42. 10.1016/j.partic.2016.06.00110.1016/j.partic.2016.06.001 ↗
43. 10.1039/c3nr04131j10.1039/c3nr04131j ↗
44. 10.3724/SP.J.1123.2015.1201410.3724/SP.J.1123.2015.12014 ↗
45. 10.1007/s00216-005-3388-910.1007/s00216-005-3388-9 ↗
46. 10.1080/00032719.2012.72110510.1080/00032719.2012.721105 ↗
47. 10.1016/j.btre.2015.08.00610.1016/j.btre.2015.08.006 ↗
48. 10.1016/j.jbiotec.2015.03.01410.1016/j.jbiotec.2015.03.014 ↗
49. 10.1016/j.talanta.2015.02.00910.1016/j.talanta.2015.02.009 ↗
50. 10.1007/s00604-016-1904-610.1007/s00604-016-1904-6 ↗
51. 10.1093/nar/gkw13610.1093/nar/gkw136 ↗
52. 10.1016/S0165-022X(01)00221-410.1016/S0165-022X(01)00221-4 ↗
53. 10.1002/bab.127610.1002/bab.1276 ↗
54. 10.1021/ac202993p10.1021/ac202993p ↗
55. Wang W · Int J Pharm · 2003 · 259 · 1
56. Sharafi Z · Trends Pept Protein Sci · 2016 · 1 · 20
57. 10.1016/j.aca.2010.10.03210.1016/j.aca.2010.10.032 ↗
58. Tabarzad M · Avicenna J Med Biotechnol · 2017 · 9 · 109
59. Vahidi h · Iran J Pharm Res · 2017 · 16 · 734